Neurocrine Biosciences Company Profile (NASDAQ:NBIX)

Analyst Ratings

Consensus Ratings for Neurocrine Biosciences (NASDAQ:NBIX) (?)
Ratings Breakdown: 10 Buy Rating(s)
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $63.90 (27.21% upside)

Analysts' Ratings History for Neurocrine Biosciences (NASDAQ:NBIX)
Show:
DateFirmActionRatingPrice TargetActions
6/29/2016HC WainwrightInitiated CoverageBuy$80.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
6/8/2016Jefferies GroupReiterated RatingBuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
6/7/2016Piper Jaffray Cos.Reiterated RatingOverweight$96.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
6/1/2016Leerink SwannReiterated RatingOutperform$63.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
5/8/2016Robert W. BairdReiterated RatingBuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
5/4/2016JPMorgan Chase & Co.Reiterated RatingBuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
4/12/2016BMO Capital MarketsReiterated RatingOutperform$57.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
2/12/2016Cowen and CompanyReiterated RatingBuy$65.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
11/2/2015NomuraBoost Price TargetBuy$34.00 -> $43.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
11/2/2015Deutsche Bank AGBoost Price TargetBuy$35.00 -> $45.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
3/4/2015Barclays PLCInitiated CoverageOverweight$60.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
2/5/2015Royal Bank Of CanadaInitiated CoverageOutperform$40.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
11/4/2014MKM PartnersReiterated RatingBuy$20.00 -> $22.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
(Data available from 7/30/2014 forward)

Earnings

Earnings History for Neurocrine Biosciences (NASDAQ:NBIX)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallActions
8/3/2016        
5/5/2016Q1($0.29)($0.22)$15.43 million$15.00 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
2/11/2016Q415($0.32)($0.34)$3.33 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
10/29/2015Q315($0.25)($0.40)$6.66 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
7/29/2015Q2($0.29)($0.28)$0.41 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
4/30/2015Q115($0.30)($0.01)$19.76 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
2/9/2015Q414($0.24)($0.26)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/3/2014Q314($0.21)($0.21)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
8/6/2014Q214($0.18)($0.18)$0.12 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
4/30/2014Q114($0.19)($0.17)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
2/6/2014Q413($0.17)($0.16)$0.79 million$0.73 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
10/29/2013Q313($0.20)($0.17)$0.79 million$0.73 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
7/25/2013Q2 2013($0.20)($0.18)$0.77 million$0.73 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
5/2/2013Q1 2013($0.18)($0.18)$1.07 million$0.70 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
2/8/2013Q4 2012($0.08)$0.14$9.43 million$21.90 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
10/31/2012Q312($0.05)($0.05)$10.28 million$9.40 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
7/31/2012($0.03)($0.01)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
5/2/2012($0.01)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
10/31/2011$0.19$0.56ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
7/28/2011$0.04$0.04ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
5/3/2011$0.05$0.05ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
2/10/2011$0.04$0.05ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Neurocrine Biosciences (NASDAQ:NBIX)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20162($0.26)($0.25)($0.26)
Q2 20162($0.52)($0.47)($0.50)
Q3 20161($0.55)($0.55)($0.55)
Q4 20162($0.64)($0.62)($0.63)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Neurocrine Biosciences (NASDAQ:NBIX)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for Neurocrine Biosciences (NASDAQ:NBIX)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionActions
5/25/2016Richard F PopsDirectorSell15,000$46.72$700,800.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/16/2016Christopher Flint ObrienInsiderSell25,000$45.00$1,125,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
4/11/2016Kyle GanoInsiderSell41,770$44.02$1,838,715.40View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
4/6/2016Christopher Flint ObrienInsiderSell25,000$45.00$1,125,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
2/3/2016Haig P BozigianInsiderSell1,375$38.13$52,428.75View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
2/3/2016Kevin Charles GormanCEOSell3,125$38.04$118,875.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
2/3/2016Timothy P CoughlinCFOSell1,500$38.06$57,090.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
1/19/2016Haig P BozigianInsiderSell1,625$46.77$76,001.25View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
1/19/2016Kevin Charles GormanCEOSell3,750$46.70$175,125.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
1/19/2016Timothy P CoughlinCFOSell1,750$46.69$81,707.50View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
1/11/2016Haig P BozigianInsiderSell1,625$44.25$71,906.25View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
1/11/2016Kevin Charles GormanCEOSell3,750$44.17$165,637.50View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
1/11/2016Timothy P CoughlinCFOSell1,750$44.25$77,437.50View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/27/2015Dimitri E. GrigoriadisinsiderSell10,000$57.50$575,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/9/2015Darin LippoldtinsiderSell23,761$52.92$1,257,432.12View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
10/16/2015Haig P BozigianInsiderSell25,000$47.78$1,194,500.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
10/16/2015Kevin Charles GormanCEOSell33,500$47.77$1,600,295.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/18/2015Gary A. LyonsDirectorSell15,000$54.89$823,350.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
7/20/2015Dimitri E GrigoriadisInsiderSell19,646$55.00$1,080,530.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
7/20/2015Timothy P CoughlinCFOSell20,000$55.00$1,100,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
7/13/2015Dimitri E GrigoriadisInsiderSell10,000$50.00$500,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
7/13/2015Timothy P CoughlinCFOSell20,000$50.00$1,000,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/23/2015W Thomas MitchellDirectorSell15,000$49.35$740,250.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/8/2015Christopher Flint ObrienInsiderSell10,000$45.00$450,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/8/2015Timothy P CoughlinCFOSell60,000$45.08$2,704,800.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/24/2015Gary A LyonsDirectorSell30,000$41.53$1,245,900.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/24/2015Kevin Charles GormanCEOSell40,000$41.53$1,661,200.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
2/10/2015Dimitri E GrigoriadisInsiderSell20,000$35.00$700,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
1/16/2015Christopher Flint ObrienInsiderSell1,750$30.79$53,882.50View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
1/16/2015Kevin Charles GormanCEOSell3,750$30.79$115,462.50View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
1/12/2015Kevin Charles GormanCEOSell3,750$28.43$106,612.50View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
1/12/2015Kyle GanoInsiderSell1,250$28.41$35,512.50View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
1/12/2015Timothy P CoughlinCFOSell1,750$28.37$49,647.50View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
1/8/2015Dimitri E GrigoriadisInsiderSell30,000$27.35$820,500.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
1/8/2015Kevin Charles GormanCEOSell25,000$27.39$684,750.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
1/8/2015Timothy P CoughlinCFOSell10,000$27.25$272,500.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
1/5/2015Dimitri E GrigoriadisInsiderSell2,500$22.76$56,900.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
1/2/2015W Thomas MitchellDirectorSell8,000$22.79$182,320.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/19/2014Christopher Flint ObrienInsiderSell20,000$24.02$480,400.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/19/2014Kevin Charles GormanCEOSell70,000$23.41$1,638,700.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/19/2014Timothy P CoughlinCFOSell30,000$23.46$703,800.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/17/2014Kyle GanoInsiderSell4,957$22.50$111,532.50View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/15/2014Dimitri E GrigoriadisInsiderSell12,794$22.35$285,945.90View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/12/2014Kyle GanoInsiderSell4,043$22.50$90,967.50View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/11/2014Christopher Flint ObrienInsiderSell40,000$21.82$872,800.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/10/2014Timothy P CoughlinCFOSell20,000$21.48$429,600.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/10/2014W Thomas MitchellDirectorSell7,000$21.90$153,300.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/28/2014Timothy P CoughlinCFOSell10,000$20.14$201,400.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/24/2014Christopher Flint ObrienInsiderSell5,463$19.53$106,692.39View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
10/31/2014Timothy P CoughlinCFOSell10,000$19.00$190,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
10/30/2014Timothy P CoughlinCFOSell20,000$18.31$366,200.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
10/1/2014W Thomas MitchellDirectorSell1,275$15.50$19,762.50View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/15/2014Gary A LyonsDirectorSell20,000$15.66$313,200.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
1/17/2014Dimitri GrigoriadisInsiderSell25,000$20.00$500,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
1/10/2014Christopher Flint ObrienInsiderSell6,750$18.88$127,440.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
1/10/2014Kevin Charles GormanCEOSell3,750$18.57$69,637.50View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
1/10/2014Timothy CoughlinCFOSell1,750$18.56$32,480.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
1/7/2014Dimitri GrigoriadisInsiderSell25,000$17.50$437,500.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
1/7/2014Kevin Charles GormanCEOSell108,000$16.76$1,810,080.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
1/7/2014Timothy CoughlinCFOSell70,000$16.75$1,172,500.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/4/2013Kyle GanoInsiderSell2,400$15.61$37,464.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/3/2013Christopher Flint ObrienInsiderSell5,000$16.00$80,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/21/2013Haig BozigianInsiderSell13,999$15.04$210,544.96View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/21/2013Timothy CoughlinCFOSell19,035$15.05$286,476.75View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/6/2013W Thomas MitchellDirectorSell1,531$14.70$22,505.70View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/5/2013Haig BozigianInsiderSell11,001$15.00$165,015.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/5/2013Timothy CoughlinCFOSell10,965$14.99$164,365.35View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
7/12/2013Christopher Flint ObrienInsiderSell5,000$14.50$72,500.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/28/2013Christopher Flint ObrienInsiderSell11,357$13.33$151,388.81View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/27/2013Haig P BozigianInsiderSell8,000$13.00$104,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/21/2013Dimitri E GrigoriadisInsiderSell46,837$12.51$585,930.87View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
(Data available from 1/1/2013 forward)

Headlines

Latest Headlines for Neurocrine Biosciences (NASDAQ:NBIX)
DateHeadline
07/29/16 08:25 AMBulls and Bear in Spotlight: Citigroup Inc. (NYSE:C), Neurocrine Biosciences Inc. (NASDAQ:NBIX), Digital Realty ... - Seneca Globe
07/28/16 03:28 PMNeurocrine Announces Initiation of a Long-Term Phase II Clinical Study of VMAT2 Inhibitor Valbenazine in Tourette Syndrome - [at noodls] - SAN DIEGO, July 28, 2016 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NASDAQ: NBIX) announced today that it has initiated a Phase II clinical trial for NBI-98854 (valbenazine), a highly selective small ...
07/28/16 03:04 PM4:04 pm Neurocrine Biosci initiates a Phase II clinical trial for NBI-98854 in children, adolescents and adults with Tourette syndrome -
07/28/16 08:36 AMShort Interest In Neurocrine Biosciences Jumps 14%
07/27/16 05:43 PMNeurocrine Biosciences Announces Conference Call and Webcast ... - PR Newswire (press release)
07/27/16 05:43 PMAnalysts Observing Stocks: Teva Pharmaceutical Industries Limited (NYSE:TEVA) , Neurocrine Biosciences, Inc ... - Street Updates
07/27/16 12:38 PMNeurocrine Biosciences Announces Conference Call and Webcast to Report Second Quarter 2016 Results - [at noodls] - SAN DIEGO, July 27, 2016 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) announced today that the Company will report its second quarter 2016 results after the Nasdaq market closes on Wednesday, ...
07/25/16 05:28 PMNeurocrine Biosciences Larger Than S&P 500 Component CSRA
07/21/16 05:40 PMShares Positive Over the Past Month: Neurocrine Biosciences Inc. (NASDAQ:NBIX) - TGP
07/21/16 05:40 PMNeurocrine Biosciences, Inc. (NASDAQ:NBIX): Sell-Side Ratings and Company Earnings Glance - Engelwood Daily
07/21/16 05:40 PMBlue Jay Capital Management LLC Increased Neurocrine Biosciences INC (NASDAQ:NBIX) by $6.10 Million as Shares ... - Consumer Eagle
07/20/16 12:11 PMNeurocrine Biosciences, Inc. – Value Analysis (NASDAQ:NBIX) : July 20, 2016 -
07/19/16 07:15 AMNeurocrine Biosciences, Inc. breached its 50 day moving average in a Bullish Manner : NBIX-US : July 19, 2016 -
07/18/16 05:30 PMPerceptive Advisors LLC Increased Neurocrine Biosciences INC (NASDAQ:NBIX) by $8.77 Million as Shares Declined - Consumer Eagle
07/18/16 05:30 PMAre Analysts Bullish Neurocrine Biosciences, Inc. (NASDAQ:NBIX) After Last Week? - Consumer Eagle
07/18/16 05:30 PMNeurocrine Biosciences, Inc. (NASDAQ:NBIX) Wall Street Analyst Recommendation Outlook - TGP
07/15/16 10:06 AMConsensus Target and Stock Rating Report: Neurocrine Biosciences, Inc. (NASDAQ:NBIX) - Telanagana Press
07/13/16 05:44 PMShort Interest In Neurocrine Biosciences Decreases By 30%
07/12/16 09:45 AMNeurocrine Biosciences Incorporated (NASDAQ:NBIX) Short Interest Decreased By 0.9% - Consumer Eagle
07/11/16 05:13 PM[$$] Lawrence Bock, Pioneering Biotech Investor, Dies at 56 -
07/10/16 04:48 PMStock Performance Rundown on: Neurocrine Biosciences Inc. (NASDAQ:NBIX) - Press Telegraph
07/10/16 04:48 PMStock on the Rise for the Quarter: Neurocrine Biosciences Inc. (NASDAQ:NBIX) - Engelwood Daily
07/10/16 04:48 PMNext Weeks Broker Price Targets For Neurocrine Biosciences, Inc. (NASDAQ:NBIX) - Fiscal Standard
07/07/16 07:13 AMNeurocrine Biosciences, Inc. breached its 50 day moving average in a Bullish Manner : NBIX-US : July 7, 2016 -
07/06/16 10:00 AMNeurocrine Biosciences, Inc. (NASDAQ:NBIX) Updated Price Targets - FTSE News
07/06/16 10:00 AMBroker Outlook For The Week Ahead Neurocrine Biosciences, Inc. (NASDAQ:NBIX) - Fiscal Standard
07/06/16 10:00 AMNeurocrine Biosciences Inc (NASDAQ:NBIX): Stock Sentiment - Engelwood Daily
07/06/16 10:00 AMWill Neurocrine Biosciences, Inc. (NASDAQ:NBIX) Surprise Analysts? - Investor Newswire
07/03/16 04:49 PMPerceptive Advisors LLC Increased Neurocrine Biosciences INC (NASDAQ:NBIX) by $8.77 Million as Shares Declined - Press Telegraph
07/03/16 04:49 PMShare Performance Recap for: Neurocrine Biosciences Inc. (NASDAQ:NBIX) - Press Telegraph
07/01/16 08:12 AMBlue Jay Capital Management LLC Increased Neurocrine Biosciences INC (NASDAQ:NBIX) by $6.10 Million as Shares ... - Press Telegraph
07/01/16 08:12 AMShort Term Price Target on Neurocrine Biosciences (NBIX) - Trade Calls
06/30/16 05:43 PMH.C. Wainwright covered (NYSE:NBIX) Neurocrine Biosciences, increasing its stock price target to $80 earlier today
06/30/16 10:07 AMInside Neurocrine Biosciences’ Focus on Tourette Syndrome -
06/30/16 08:07 AMPositive Top-Line Data May Help Secure FDA Approval for Valbenazine -
06/29/16 05:16 PMNeurocrine Biosciences Inc. Stock Momentum Hits Weakness - CML News
06/29/16 08:11 AMNeurocrine Biosciences Inc. (NBIX) Jumps 5% on June 28 - Equities.com
06/28/16 10:14 AMNeurocrine Biosciences Incorporated (NASDAQ:NBIX) Short Interest Decreased By 0.9% - Engelwood Daily
06/28/16 10:14 AMTop Stock Pick for Quarter: Neurocrine Biosciences Inc. (NASDAQ:NBIX) - Engelwood Daily
06/25/16 09:07 AMCommit To Purchase Neurocrine Biosciences At $39, Earn 18.8% Annualized Using Options
06/23/16 08:03 AMNeurocrine Biosciences, Inc. (NASDAQ:NBIX) Current Analyst Ratings - Fiscal Standard
06/22/16 05:14 PMNotable Runners: QUALCOMM, Inc. (NASDAQ:QCOM), Neurocrine Biosciences, Inc. (NASDAQ:NBIX) - NYSE Journal (press release)
06/20/16 07:01 AMNeurocrine Biosciences, Inc. (NASDAQ:NBIX) Analyst Price Targets For The Coming Week - Fiscal Standard
06/11/16 08:13 AMAnalysts Review of Stocks: Cerus Corporation (NASDAQ:CERS) , Neurocrine Biosciences, Inc. (NASDAQ:NBIX) - Street Updates
06/11/16 08:13 AMStocks Earnings Report: Big Lots Inc. (NYSE:BIG), Neurocrine Biosciences Inc. (NASDAQ:NBIX) - Beacon Chronicle
06/06/16 09:03 AMNeurocrine Biosciences, Inc. (NASDAQ:NBIX) Stock Update & Estimates - Stock Tick Tock
06/06/16 09:03 AMTrading Overview of Two Stocks: Neurocrine Biosciences, Inc. (NASDAQ:NBIX) , Sangamo BioSciences, Inc. (NASDAQ ... - Street Updates
06/05/16 08:00 AMPerformance Review for Neurocrine Biosciences Inc. (NASDAQ:NBIX) - HNN
06/05/16 08:00 AMNeurocrine Biosciences, Inc. (NBIX) Given “Buy” Rating at JPMorgan Chase & Co. - Let Me Know About This
06/04/16 08:11 AMPerceptive Advisors LLC Increased Neurocrine Biosciences INC (NASDAQ:NBIX) by $8.77 Million as Shares Declined - CCH Daily News

Social

About Neurocrine Biosciences

Neurocrine Biosciences logoNeurocrine Biosciences, Inc. is engaged in the development of pharmaceutical products focused on neurological and endocrine-based diseases and disorders. The Company's two lead late-stage clinical programs are Elagolix, a gonadotropin-releasing hormone (GnRH) antagonist for women's health that is partnered with AbbVie Inc. (AbbVie), and NBI-98854 (valbenazine), a vesicular monoamine transporter 2 (VMAT2) inhibitor for the treatment of movement disorders. The Company focuses on developing NBI-640756 against Essential tremor. Its research and development focuses on addressing diseases and disorders of the central nervous and endocrine systems, which include therapeutic categories ranging from hypothalamic-pituitary-adrenal (HPA) disorders to stress-related disorders and neurological/neuropsychiatric diseases. Its Corticotropin-Releasing Factor (CRF) is a hypothalamic hormone released directly into the hypophyseal portal vasculature.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Drugs - Generic
  • Sub-Industry: Biotechnology
  • Exchange: NASDAQ
  • Symbol: NBIX
  • CUSIP: 64125C10
Key Metrics:
  • Previous Close: $50.23
  • 50 Day Moving Average: $46.74
  • 200 Day Moving Average: $43.39
  • P/E Ratio: N/A
  • P/E Growth: 2.85
  • Market Cap: $4.35B
  • Beta: 0.67
  • Current Year EPS Consensus Estimate: $-1.94 EPS
  • Next Year EPS Consensus Estimate: $-1.79 EPS
Additional Links:
Neurocrine Biosciences (NASDAQ:NBIX) Chart for Saturday, July, 30, 2016